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Apoferritin is a complex protein with a number of possibilities for drug delivery and drug targeting 
technologies, as it could be considered as the future self-assembling, not-toxic protein drug 
delivery carrier. Few years ago, this concept was a reality; nowadays, after more than 10 years of 
research, a clear painting of Apoferritin, loaded with drugs, is lacking, in terms of protocols of 
formulation, characterization, drug release and application.  Therefore, a critical evaluation and 
overall understanding of Apoferritin is due to speed up the possibilities for its translatability into 
clinical application.  
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Main Text 
In order to reach the ambitious aim of Ehrlich’s “magic bullet” of developing drug delivery systems 
(DDS) selectively binding the site of diseases or even the diseased cells, without further affecting 
patients’ health with side effects, a number of promising approaches were developed in the last 
decades.  
To fit with the ideal design, the “perfect” DDS should be characterized by good properties in: 
1. Pharmaceutics (i.e. ability to efficiently load different kinds of therapeutic molecules, drug-
release profiles adequate to pathologies treatment, high stability) 
2. Safety (i.e. biocompatibility) 
3. Selectivity (i.e. specific recognition on targeted site, lowering side effects) 
 
The need to find biocompatible materials for the development of DDS strongly drove the research 
to a concrete tentative of replacing synthetic materials, as porous hollow silica or not-fully 
biocompatible polymers, with natural materials, endogenously present within the body, thus more 
acceptable and considered as self by the immune defense system.   
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Looking at this scope, endogenous self-assembling proteins could be a strategic choice, leading to 
obtain DDS able to efficiently load molecules, considered as non-toxic for the organism and 
therefore safe.  
More recently, the attention of the research focused on Apoferritin (APO), from ferritin family, a 
uniform regular self-assemblies nano-sized protein, showing excellent biocompatibility and unique 
architecture able to stabilize small active molecules in its inner core. The low dimension, spherical 
shape and high homogeneity [1] are among the key aspects that support the wide interest in APO 
cage. This novel DDS could lead to longer circulation half-life and eventually to better 
accumulation rates, in comparison with synthetic DDS (i.e. polymeric NPs or liposomes), 
characterized by higher size (50-200 nm) and less homogeneity. Moreover, APO is fully 
biocompatible and a-toxic, which is not a common feature for all the conventional nano-DDS.  
Beside this aspect on safety/biocompatibility, a major interest in APO research lies in “targeting” 
abilities. These features are classically addressed by surface conjugation of nano-DDS with ligands 
(peptide, antibodies…) able to target the diseased sites.   
This inevitably lead to the “over-crowding” of the surface of carriers, with a number of issues to be 
solved from both technological (i.e. production reproducibility, surface characterization) and 
biological points of view (i.e. interaction with bloodstream proteins, protein corona composition, 
safety and immune reaction), and overall the biocompatibility of the final structure 
On the contrary, APO possesses site-specific targeting potential, as they can be recognized and 
internalized by Ft-binding receptors, such as the transferrin receptor 1 (TfR1). The overexpression 
of these receptors especially on the surface of malignant cells is one of the most important 
reasons for the growing interest of APO in the application of field of cancer treatment and 
diagnosis. This overexpression should be considered as an increased presence of TfR in malignant 
cells, but not as a unique expression of cancer cells. In fact, transferrin receptors are present onto 
many other cells, greatly varying among cells depending on tissues, as TfR could be easily found in 
basal epidermis, endocrine pancreas, hepatocytes, Kupfer cells, testis and pituitary gland [2]. Thus, 
on the basis of these evidences, the potentiality of APO widens to the application in other fields of 
nanomedicine as gene therapy, immunology or liver pathology. 
 
Apoferritin: from the dream to the reality 
 
Notwithstanding these good premises, some limits emerged in the application of APO as DDS, 
mainly connected to pharmaceutical formulation, characterization and standardization of process, 
but also to its biosafety. In particular, a couple of aspects is up-to-date unclear and poorly 
analyzed and therefore to be strongly investigated and ameliorated to allow APO to play a major 
role in DDS, namely:  
 
1. Pharmaceutical Issues  
2. Biosafety Issues 
 
The Pharmaceutical Issues 
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As evident from the literature outputs, due to the stringent requirements of loading protocols, 
only a limited number of drugs could be efficiently encapsulated and not always the efficacy of 
drug/APO complex is higher respect to free drug. Actually, the plethora of experiments on APO 
formulation did not produce a standardized protocol that is able to clearly furnish a reproducible 
unfolding/refolding of the protein, and especially when the drug is present and ready to be 
loaded. Chemico-physical properties of drugs as molecular weight, pKa and charge should be 
taken into great account in planning their encapsulation in the APO core. In this view, a particular 
attention should be devoted to pH values; as a matter of fact, the choice of pH values of the 
starting solution strongly impact on the type and distribution of charges onto the surface of the 
protein and therefore could determine rearrangement of the protein conformation. Besides, also 
pH values applied during the disassembly-reassembly protocol become critical to obtain an 
effective loading. Not only pH values, but also many other variables can affect encapsulation 
efficiency into APO protein nanocarrier as: i) ionic concentration; ii) interactions between ions in 
solution and functional groups onto protein surface; iii) temperature, which could limit of stability 
of the protein by inducing its unfolding and denaturation; iv) protein concentration which can 
increase the frequency of molecular collisions and can promote aggregation; v) mechanical stress 
caused by processes such as mixing, stirring, filtration, dialysis, concentration etc. [3]. 
From this point of view, synthetic DDS offer a larger versatility of formulation as, by simply 
changing the composition of the carriers or the formulation technique, a greater number of 
molecules could be encapsulated or even adsorbed. Moreover, synthetic DDS are studied to reach 
the goal of achieving controlled&targeted drug release, thus limiting well-known side effects of 
high systemic or off-target exposure. In the case of APO, it is very hard to modulate drug release 
from the inner cage, especially depending on their chemico-physical properties. That way, ions, 
allowed to enter/exit through pores, could be modulated, but larger molecules could be released 
from the inner core only as consequence of protein denaturation once in cellular acidic 
compartment, thus strongly impacting and often decreasing the possibility for release modulation 
[4].  
Thus, a rationale planning of APO as DDS should be based on the “prediction/evaluation” of the 
combination of the formulative variables, which will govern both the loading efficiency and drug 
release kinetics. In fact, the possibility for the drug to penetrate and to escape through the APO 
inner channels is strongly function of drug/protein electrostatic interactions. These interactions 
impact also on the structural rearrangement of APO, as, depending on its charges, any 
electrostatic interaction with the drug will strongly affect the correct reassembly of the protein. 
This electrostatic interaction between charged drug and charged protein will also play an 
important role both on the stability of the encapsulation and on the un-wanted absorption of the 
drug on the protein surface. 
Finally, a major issue is surely related to the chemico-physical characterization of APO during all 
the processes of formulation along with the characterization of the final loaded APO-based DDS. 
This particular aspect is fully addressed in the review we are proposing in this issue.  
The Biosafety Issues 
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It is a common idea that proteins are generally safe and non-toxic; however the reaction after 
administration of heterologous APO could lead to (i) activation of immune system against foreign 
proteins, similar to immune response against pathogens or vaccines; and (ii) breach of B and T cell 
tolerance to autologous proteins  [5,6], finally resulting in the production of anti-therapeutic 
protein antibodies [known as anti-drug antibodies (ADAs)] able to neutralize or otherwise to 
compromise the clinical effect of therapeutics [7]. A number of studies use ferritin of animal 
source, mainly derived from horse [8] and pig [9], or in other cases by means of exploitation of 
recombinant proteins [10,11] and often, the choice of the APO derived from economic aspects. In 
fact, horse spleen ferritin is cheaper with respect to human ferritin but frequently the researchers 
underestimated the impact on biosafety and in vivo response.  
Thus, the protein source, its purity and its final rearrangement could deeply affect the safety 
profiles of the protein and the final applicability of the DDS.  
Moreover, the advantage of use a natural molecule as starting material for DDS is drastically 
affected when ex vivo engineering processes are performed in order to link targeting moieties 
onto the DDS surface. The use of solvent, chemical reagents and ligands obviously impact on the 
biocompatibility of the formulation as the protein conformation deeply suffers in terms of stability 
and maintenance of the tertiary/quaternary structures of the modified proteins. Moreover, the 
presence of ligand could interfere with the surface integrity, governing or altering the overall 
biodistribution and body-distribution.  
 
Expert Opinion 
Several evidences provide for the suitability of APO as protein-based DDS, featured by a number of 
advantages regarding the biocompatibility and application in pathologies, especially in the case of 
treatment and imaging of cancer. As any new “application”, the starting point consists of the 
direct evidence of efficacy in treatment, but, as rule, immediately after the first proofs-of-concept, 
a complete study on formulation, scale-up, translatability, biocompatibility and biodistribution is 
strongly required.  
It is evident that APO based nano-DDS are up-to-date in the middle of this path. Therefore, 
especially a multidisciplinary research effort should be given in order to complete the overall 
“painting” of APO application and formulation and to give strong impulse to the development and 
clinical translatability of these novel and promising DDS.      
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